Immutep Ltd. has released a corporate presentation highlighting its leadership in LAG-3 immunotherapy. The company is focusing on four clinical-stage assets and a preclinical program aimed at combating cancer and autoimmune diseases. The presentation details their first-in-class lead clinical candidates, including Efti, a novel MHC II agonist showing strong efficacy and a favorable safety profile in multiple cancers. Additionally, Immutep is conducting a Phase III trial in collaboration with MSD, evaluating Efti in combination with KEYTRUDA and chemotherapy for first-line treatment of non-small cell lung cancer. Immutep maintains full commercial rights to Efti. The company has multiple collaborations with large pharma and leading institutions. Immutep reports a strong intellectual property portfolio and a solid financial position with cash and cash equivalents of approximately A$146.25 million as of March 2025. You can access the full presentation through the link below.